Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A semiconductor packaging structure includes a lead frame, a first thermally conductive layer, a second thermally conductive layer, a chip, and an encapsulation body. The first thermally conductive layer is disposed on a surface of the lead frame, and includes a plurality of first silver powder particles. The second thermally conductive layer is disposed on the first thermally conductive layer, and includes a resin and a plurality of second silver powder particles. The first silver powder particles are smaller in size than the second silver powder particles. The chip is disposed on the second thermally conductive layer. A bottom surface of the chip and a portion of a side surface of the chip contact the second thermally conductive layer. The encapsulation body covers the lead frame, the first thermally conductive layer, the second thermally conductive layer, and the chip.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A semiconductor device includes: a first wire bonding area with a first bonding pad, a second wire bonding area with a second bonding pad, and a first bonding wire connecting the first bonding pad to the second bonding pad. The first bonding wire includes a lower pressing section and a first line segment connecting the lower bonding part to the first bonding pad. A distance between the lower pressing section and a plane where the second wire bonding area is located is defined as a first height, which is smaller than 400 ?m, a length of an orthographic projection of the first bonding wire on the plane is defined as a first length, a length of an orthographic projection of the first line segment on the plane is defined as a second length, and the second length is 20%-80% of the first length.

Abstract: The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.

Abstract: The present invention discloses Stenotrophomonas maltophilia GYH and its application in degrading chlorinated hydrocarbon pollutants, and the application is carried out as follows: resting cells obtained by spreading cultivation of Stenotrophomonas maltophilia GYH are added to a pH=5-8 inorganic salt medium, and then a chlorinated hydrocarbon pollutant is added, and the cells are cultured at 20-35° C. and 140-180 rpm to degrade the pollutant. The concentration of chlorinated hydrocarbon pollutant which can be removed by Stenotrophomonas maltophilia GYH ranges from 2.9 mg/L to 8.93 mg/L. Therefore, the Stenotrophomonas maltophilia has a highly efficient degradation ability for similar industrial pollutants and is able to withstand high concentrations of these pollutants.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Methods for USB signal communication over an optical link are described. One aspect includes detecting connection of a device circuit to a USB device. The detecting may further include transmitting an electrical pulse through a reactive network, and detecting a change in a delay associated with the electrical pulse responsive to connecting the device circuit to the USB device. An optical signal associated with the detected connection may be transmitted to a host circuit via an optical communication channel.

Abstract: Systems and methods for optical transmission of one-or-more out-of-band signals associated with audio-video signal communication are described. In one aspect, an optical receiver receives a first out-of-band electrical signal and a second out-of-band electrical signal from a video sink. The first out-of-band electrical signal may correspond to an audio-video stream previously received or concurrently being received from a video source optical transmitter at the optical receiver. The second out-of-band electrical signal may also correspond to the audio-video stream. The optical receiver may combine the first out-of-band electrical signal and the second out-of-band electrical signal into a transmit electrical signal. In one aspect, the optical receiver converts the transmit electrical signal into an optical signal, and transmits the optical signal to an optical transmitter via an optical communication channel.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A rotary positioning adjustment device includes a shaft sleeve and a connecting rod. A reel is fixedly connected with an end of the connecting rod; a fixed seat is sleeved on the connecting rod; the reel is arranged in the fixed seat; and a power storage assembly is installed in the shaft sleeve. The power storage assembly includes a power input piece, a second torsion spring and a power output piece; a first support leg of the second torsion spring is connected in a hooked mode with one side of an input block of the power input piece, and a second support leg of the second torsion spring is connected in a hooked mode with the other side of the input block. A curtain includes the rotary positioning adjustment device.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Systems and methods to implement a USB and Thunderbolt optical signal transceiver are described. One method includes detecting presence of a USB sideband signal received over an optical communication channel and associated with a USB communication request. Responsive to the detecting, the method may determine that the USB communication request corresponds to a USB communication mode and perform a sideband negotiation. The USB communication mode may be enabled. A specified number of channels associated with the USB communication request may be determined. USB communication may be performed using the specified number of channels over the optical communication channel in the USB communication mode.